Abstract
Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Current Pharmaceutical Design
Title: Tissue Transport of Anti-cancer Drugs
Volume: 8 Issue: 22
Author(s): Jan Lankelma
Affiliation:
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Abstract: Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Export Options
About this article
Cite this article as:
Lankelma Jan, Tissue Transport of Anti-cancer Drugs, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393512
DOI https://dx.doi.org/10.2174/1381612023393512 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Application of 3D Biomimetic Models in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Synthesis, Characterization and Biological Evaluation of Indole-Pyrazole Amalgamated α-Cyano Substituted Chalcones
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Hepatocyte Growth Factor and Macrophage-stimulating Protein “Hinge” Analogs to Treat Pancreatic Cancer
Current Cancer Drug Targets Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets New Hope for Intervertebral Disc Degeneration: Bone Marrow Mesenchymal Stem Cells and Exosomes Derived from Bone Marrow Mesenchymal Stem Cell Transplantation
Current Gene Therapy Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Gene Electrotransfer: A Mechanistic Perspective
Current Gene Therapy Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design